Showing results (101-110 of 129) with videos related to

Sort By:
Pageof 13
The Journal of Rheumatology|May 3, 2016
Let's Talk about Inclusion: A Report on Patient Research Partner Involvement in the GRAPPA 2015 Annual MeetingMaarten de Wit, Willemina Campbell, Laura C Coates, et al.
Rheumatology (Oxford, England)|December 26, 2016
Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritisWilliam Tillett, Gavin Shaddick, Amelia Jobling, et al.
Advances in Therapy|August 10, 2022
The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 TrialJeffrey R Curtis, Iain B McInnes, Proton Rahman, et al.
RMD Open|October 25, 2023
Construct validity and responsiveness of feasible composite disease activity measures for use in daily clinical practice in patients with psoriatic arthritisFazira R Kasiem, Marc R Kok, Jolanda J Luime, et al.
The Journal of Rheumatology|April 16, 2021
Test-retest Reliability for HAQ-DI and SF-36 PF for the Measurement of Physical Function in Psoriatic ArthritisYing Ying Leung, William Tillett, Pil Hojgaard, et al.
Rheumatology and Therapy|April 29, 2021
Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 StudyPhilip J Mease, Apinya Lertratanakul, Kim A Papp, et al.
The Journal of Rheumatology|February 16, 2022
Plain Radiographic Instruments for Structural Damage in Peripheral Joints in Psoriatic Arthritis: A Report From the GRAPPA-OMERACT Working GroupAnna Antony, Richard Holland, Ashish J Mathew, et al.
RMD Open|March 25, 2022
Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trialsIain B McInnes, Andrew J K Ostor, Philip J Mease, et al.
The Journal of Rheumatology. Supplement|June 3, 2020
The GRAPPA-OMERACT Working Group: 4 Prioritized Domains for Completing the Core Outcome Measurement Set for Psoriatic Arthritis 2019 UpdatesYing Ying Leung, William Tillett, Ana-Maria Orbai, et al.
The Journal of Rheumatology|July 1, 2026
Bimekizumab Improves Health Status and Work Productivity, With Reduced Productivity Costs, to 3 Years in Axial Spondyloarthritis and Psoriatic ArthritisElena Nikiphorou, William Tillett, Atul Deodhar, et al.
Pageof 13